Equities

4Dmedical Ltd

4Dmedical Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.52
  • Today's Change-0.005 / -0.95%
  • Shares traded337.16k
  • 1 Year change+9.47%
  • Beta1.9455
Data delayed at least 20 minutes, as of Nov 08 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in AUD

The 3 analysts offering 12 month price targets for 4DMedical Ltd have a median target of 0.85, with a high estimate of 1.10 and a low estimate of 0.75. The median estimate represents a 63.46% increase from the last price of 0.52.
High111.5%1.10
Med63.5%0.85
Low44.2%0.75

Earnings history & estimates in AUD

4DMedical Ltd reported annual 2024 losses of -0.11 per share on Aug 29, 2024.
Average growth rate-2,645.00%
More ▼

Revenue history & estimates in AUD

4DMedical Ltd had revenues for the full year 2024 of 3.75m. This was 422.11% above the prior year's results.
Average growth rate+258.68%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.